Tenatumomab is a monoclonal antibody that targets the protein CD3, which is a component of the T-cell receptor complex, thereby modulating T-cell activity. It is primarily investigated for its potential therapeutic applications in oncology, particularly in the treatment of various types of cancer by enhancing the immune response against tumor cells. As a biologic agent, Tenatumomab is characterized by its specificity for CD3, which plays a crucial role in T-cell activation and proliferation. The substance is produced through recombinant DNA technology, ensuring a high degree of purity and consistency. Its mechanism of action involves the engagement of T-cells to recognize and attack cancer cells, making it a candidate for immunotherapy. The development and clinical use of Tenatumomab are subject to rigorous testing for efficacy and safety, as is standard for monoclonal antibodies. Overall, Tenatumomab represents a significant advancement in targeted cancer therapies, leveraging the body's immune system to combat malignancies.

Tenatumomab

1412891-40-7: Tenatumomab is a monoclonal antibody that targets the protein CD3, which is a component of the T-cell receptor complex, thereby modulating T-cell activity. It is primarily investigated for its potential therapeutic applications in oncology, particularly in the treatment of various types of cancer by enhancing the immune response against tumor cells. As a biologic agent, Tenatumomab is characterized by its specificity for CD3, which plays a crucial role in T-cell activation and proliferation. The substance is produced through recombinant DNA technology, ensuring a high degree of purity and consistency. Its mechanism of action involves the engagement of T-cells to recognize and attack cancer cells, making it a candidate for immunotherapy. The development and clinical use of Tenatumomab are subject to rigorous testing for efficacy and safety, as is standard for monoclonal antibodies. Overall, Tenatumomab represents a significant advancement in targeted cancer therapies, leveraging the body's immune system to combat malignancies.

Tenatumomab (ST2146) is a murine anti-tenascin-C monoclonal antibody used in the study of immune system diseases and lymphomas.

Anti-Tenascin C monoclonal antibody, treatment of cancer

CAS 1412891-40-7

Tenatumomab

Tenatumomab

Ref: 54-BUP20065

Tenatumomab

Ref: TM-T78308

Tenatumomab

Ref: 3D-CLA1173